Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julie Polson

Gastroenterology Denver, CO Medical Doctor

NPI 1154350270 CMS profile 233201

4500 E 9Th Ave, Suite 720S, Denver, CO 80220

Open in the dashboard

General payments

$8,298

533 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Polson of Denver, CO is reported in the CMS Open Payments database as having received $8,298 across 533 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $729 33
2024 General $755 35
2023 General $976 65
2022 General $1,655 80
2021 General $1,676 116
2020 General $1,350 108
2019 General $1,157 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Polson
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Julie Polson were reported at $729. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Julie Polson Gastroenterology median Middle half National median
2019 $1,157 $417 $126–$1,100 $163
2020 $1,350 $224 $74–$624 $114
2021 $1,676 $352 $106–$1,054 $132
2022 $1,655 $448 $129–$1,270 $149
2023 $976 $533 $150–$1,390 $160
2024 $755 $605 $160–$1,606 $164
2025 $729 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,187 207 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $902 95 payments
  3. Genzyme Corporation $724 22 payments
  4. Celgene Corporation $524 47 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $385 21 payments
  6. Gilead Sciences, Inc. $315 23 payments
  7. Regeneron Healthcare Solutions, Inc. $310 17 payments
  8. Pfizer Inc. $267 15 payments
  9. Braintree Laboratories, Inc. $240 16 payments
  10. QOL Medical, LLC $192 10 payments
  11. Other $1,252 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,144 521 payments
  2. Gift $130 10 payments
  3. Education $24 2 payments
Products named General payments · program years 2019–2025
  1. HUMIRA $1,629 112 payments
  2. DUPIXENT $686 20 payments
  3. RINVOQ $672 38 payments
  4. ZEPOSIA $524 47 payments
  5. CREON $522 34 payments
  6. XIFAXAN $370 29 payments
  7. TRULANCE Gastroenterology $330 36 payments
  8. XELJANZ $267 15 payments
  9. TRULANCE Gastroenterology $259 35 payments
  10. ENTYVIO $243 10 payments
  11. Other $3,122 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

592

Median for Gastroenterology: 569

Drug cost

$635,639

Median for Gastroenterology: $104,976

Branded share of claims

23.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gattex Teduglutide Brand 12 $537,605
Creon Lipase/Protease/Amylase Brand 17 $53,988
Linzess Linaclotide Brand 15 $13,095
Mesalamine Generic 19 $8,936
Colesevelam Hcl Generic 27 $5,358
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 26 $4,219
Budesonide Dr Budesonide Brand 32 $2,769
Pantoprazole Sodium Generic 197 $2,224
Colestipol Hcl Generic 37 $1,844
Mesalamine Er Mesalamine Brand 16 $1,461

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$90,237

Of which drugs: $57,903

Medicare patients

173

Average age 73

Services billed

3,715

141 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 54%
High blood pressure 53%
Osteoporosis 28%
Depression 22%
Diabetes 15%
Ischemic heart disease 14%
Cancer 14%
Chronic kidney disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $218
  • Regeneron Healthcare Solutions, Inc. $43
$261 — —
RINVOQ
  • AbbVie, Inc. $126
$126 — —
SKYRIZI
  • AbbVie, Inc. $46
$46 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $39
$39 — —
SUFLAVE
  • Braintree Laboratories, Inc. $38
$38 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

533 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record